SAN FRANCISCO – Although most of the biotech world was starting last week with a J.P. Morgan Healthcare Conference hangover, it was business as usual for the redoubtable Steve Burrill, whose life sciences venture firm, Burrill & Co., recently added Capital Fund IV to its portfolio.